A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naive Subjects With Bone Predominant Metastatic Castration-resistant Prostate Cancer(CRPC)

Trial Profile

A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naive Subjects With Bone Predominant Metastatic Castration-resistant Prostate Cancer(CRPC)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Radium 223 chloride (Primary) ; Abiraterone acetate; Prednisolone; Prednisone
  • Indications Adenocarcinoma; Bone metastases; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ERA 223
  • Sponsors Bayer
  • Most Recent Events

    • 06 Sep 2017 Planned primary completion date changed from 15 Dec 2017 to 15 May 2018.
    • 29 Mar 2017 Planned End Date changed from 1 Dec 2020 to 23 Dec 2019.
    • 22 Sep 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top